All News
Rheumatoid Synovium Characterized by Six Cell Type Phenotypes
Research work from the Accelerating Medicines Partnership (AMP: RA/SLE) Network, was published in Nature and more specifically characterizes RA synovium into several cell-type abundance phenotypes (CTAPs). Could CTAPs known disease features or more effective future therapies?
Read Article
Arthritis Increased Amongst US Veterans
A recent CDC reports estimates that in 2019–2021, 21% of U.S. adults (53.2 million) have physician diagnosed arthritis. Now, an updated report shows a larger number (~33%) of U.S. veterans having diagnosed arthritis. Compared to nonveterans, this prevalence was double in men, and 60% higher in women.
Read Article
Incidence, Microbiological Studies, and Factors Associated With Prosthetic Joint Infection After Total Knee Arthroplasty
A study of nearly 80,000 US veterans who underwent primary knee joint arthroplasty (TKA) showed the incidence of prosthetic joint infection (PJI) was highest in the first 3 months and remained elevated through 12 months compared with 12 months or more after surgery.
Read Article
ACR Reacts to 2024 Medicare Physician Fee Schedule
The American College of Rheumatology (ACR) expressed concern that the conversion factor included in the Centers for Medicare and Medicaid Services (CMS) CY 2024 Medicare Physician Fee Schedule and Quality Payment Program final rule is insufficient to address rising inflation.
Read Article
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants
A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions.
Read Article
Late Should Not Be Less (11.3.2023)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.
Read Article
H. Zoster Subunit Vaccine Efficacy with JAK Inhibitor Therapy
JAK inhibitors are known to increase the risk of herpes zoster infections between between 3-5 fold. Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV).
Read Article
Oral Surveillance Study Alters Practice at VA
Safety risks found in a postmarketing trial with the Janus-associated kinase (JAK) inhibitor tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for rheumatoid arthritis (RA) patients in the Veterans Affairs (VA) health system, researchers found.
Read Article
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitor Treatment of Skin Disorders
A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the placebo
Read Article
Optimal Management of de Quervain Tenosynovitis
The treatment of de Quervain tenosynovitis (DQT) was examined by systematic review in JAMA, suggesting that local (US-guided) corticosteroid injection plus a thumb spica immobilization was associated with significant pain-relieving and functional benefits.
Read Article
Links:
FDA Approves Infliximab Biosimilar for Subcutaneous Use
Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.
Read Article
Subcutaneous Biosimilars? (10.27.2023)
Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.
Read Article